Cue Biopharma, Inc.CUE

Cue Biopharma’s cash position at 31 March 2026 stood at $16.4 million, a figure that sounds healthier than it feels once you notice the company burned $10.9 million in operating cash during the quarter and finished with a net loss of $5.2 million. Revenue of $5.7 million was the only green number on the page, yet it scarcely covered the $6.9 million research tab. The company’s filing history shows the deficit is structural rather than incidental: operating loss hit $5.4 million for the same period. (source: SEC EDGAR 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1645460/000164546026000004/xslFormDX01/primary_doc.xml)

Cue is a clinical-stage biopharma outfit chasing “transformative therapies targeting functional cures for immunological disorders,” according to its investor pages, but the operating reality is closer to a treadmill that sprints in the wrong direction. The company’s lead programme, CUE-401, is a first-in-class bifunctional IL-2 and TGF-β molecule designed to modulate immune responses in autoimmune disease, and management now expects to open a Phase 1 trial before the fourth quarter of 2026. The filing does not state where the drug would be tested, how many patients are planned, or what primary endpoints will be tracked. (source: Cue Biopharma Announces $50.0 Million Private Placement, https://www.cuebiopharma.com/news/cue-biopharma-announces-50-0-million-private-placement/)

The company’s latest equity infusion-a $50 million private placement announced on 9 July 2026-gives it runway to fund the Phase 1 trial and maybe a quarter beyond, provided costs don’t balloon. The placement documents are not itemised in the SEC filing index, so investors cannot see which investors took part, what discount to market price was applied, or what warrants or other sweeteners were granted. The company’s cash and equivalents rose from $16.4 million at 31 March to roughly $66.4 million on announcement day if the $50 million arrived immediately, yet the 10-Q still shows current liabilities of $9.3 million and total stockholders’ equity of $21.6 million, implying the fresh capital has yet to clear the bank. (source: SEC EDGAR 10-Q, period ending 2026-03-31; SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1645460)

For context on liquidity and trading mechanics, the Nasdaq-listed line trades under the ticker CUE on the Nasdaq Capital Market. The company’s SEC submissions JSON lists a Form 8-K filed on 2 June 2026 detailing a $50 million private placement agreement, but the JSON file does not include the placement’s closing date, final proceeds, or use-of-proceeds breakdown. (source: SEC submissions JSON, https://data.sec.gov/submissions/CIK0001645460.json; SEC EDGAR 8-K, https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/d139032d8k.htm)

The company’s research-and-development expense of $6.9 million in the quarter ending 31 March 2026 exceeded product revenue of $5.7 million, a mismatch that is mathematically sustainable only with fresh capital or a sharp reduction in burn. The weighted average diluted share count rose to 4.8 million, pushing earnings-per-share down to a loss of $1.08. The company’s latest Form 3 and Form 4 filings in mid-July show multiple insider transactions coinciding with the private placement announcement, a pattern that invites questions about who is buying shares at what price and whether the timing advantages certain parties. (source: SEC EDGAR Form 3 and Form 4, 15 July 2026, https://www.sec.gov/Archives/edgar/data/1645460/000200879026000006/xslF345X06/form3-07152026_100719.xml; https://www.sec.gov/Archives/edgar/data/1645460/000200879026000004/xslF345X06/form4-07152026_100742.xml)

Management’s disclosure is concise: no guidance is provided beyond the Phase 1 timeline for CUE-401, and the company does not break out segment-level economics or geographical revenue. The evidence therefore supplies no visibility on partner economics, milestone payments, or royalty structures that might offset the cash burn. (source: SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001645460.json)